Eden Research signs exclusive option contract with Taminco
Under the agreement, Taminco will conduct marketing and regulatory trials with Eden’s nematicide product B2Y until March 31, 2016. Pending a successful outcome, Eden and Taminco will craft a global licensing arrangement.
“Eden and Taminco are both dedicating considerable resource[s] to this collaboration during the course of 2015 to ensure the product will be a success,” Eden CEO Sean Smith said.
Eden Research is an Alternative Investment Market-listed public company based near Oxford, England, with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies. Eden develops natural solutions to agricultural, medical and industrial problems, primarily focusing on using terpenes innovatively to create low-risk agricultural chemicals.
“Being a leading supplier in soil disinfection for high value crops, we are always looking for new innovative products," Taminco general manager for its crop protection division Guy Van den Bossche said. "The collaboration with Eden is a step forward to broaden our offer with complementary solutions that respond to market trends for increasing sustainability in crop protection.”
Taminco, a subsidiary of Eastman Chemical Company, is headquartered in Belgium. It produces mono-, di- and trimethylamines and derivatives including agrochemicals, feed additives and water treatment chemicals.